NovaBridge Biosciences Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
30
- Stock Symbol
-
NBP
- Investments
-
4
- Share Price
-
$0.85
- (As of Friday Closing)
NovaBridge Biosciences General Information
Description
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Contact Information
Website
www.novabridge.comCorporate Office
- 2440 Research Boulevard
- Suite 400
- Rockville, MD 20850
- United States
Corporate Office
- 2440 Research Boulevard
- Suite 400
- Rockville, MD 20850
- United States
NovaBridge Biosciences Stock Performance
As of 13-Nov-2026, NovaBridge Biosciences’s stock price is $0.85. Its current market cap is $98.6M with 116M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.85 | $0.83 | $0.78 - $5.19 | $98.6M | 116M | 483K | -$0.69 |
NovaBridge Biosciences Financials Summary
As of 30-Jun-2026, NovaBridge Biosciences has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 17,740 | 233,859 | (111,334) | (238,368) |
| Revenue | 0 | 0 | 0 | 632 |
| EBITDA | (122,808) | (95,095) | (56,204) | (90,450) |
| Net Income | (75,483) | (46,269) | (22,230) | (207,729) |
| Total Assets | 231,542 | 260,522 | 212,680 | 368,922 |
| Total Debt | 4,458 | 3,067 | 3,882 | 3,887 |
NovaBridge Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
NovaBridge Biosciences Comparisons
Industry
Financing
Details
NovaBridge Biosciences Competitors (77)
One of NovaBridge Biosciences’s 77 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Valerio Therapeutics | Formerly VC-backed | Paris, France | ||||
| Arcus Biosciences | Formerly VC-backed | Hayward, CA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Redx Pharma | Venture Capital-Backed | Macclesfield, United Kingdom |
NovaBridge Biosciences Patents
NovaBridge Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4143239-A1 | Pharmaceutical compositions containing anti-cd47 antibodies | Inactive | 30-Apr-2020 | ||
| EP-4143239-A4 | Pharmaceutical compositions containing anti-cd47 antibodies | Inactive | 30-Apr-2020 | ||
| EP-4048699-A1 | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | Inactive | 22-Nov-2019 | ||
| EP-4048699-A4 | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | Inactive | 22-Nov-2019 | ||
| WO-2021097800-A1 | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | Inactive | 22-Nov-2019 | C07K16/2827 |
NovaBridge Biosciences Signals
NovaBridge Biosciences Investments & Acquisitions (4)
NovaBridge Biosciences’s most recent deal was a Merger/Acquisition with BridgeBio for . The deal was made on 28-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| BridgeBio | 28-Oct-2025 | Merger/Acquisition | Biotechnology | ||
| NovaBridge Biosciences (VIS-101, Novel Bifunctional Biologic in the United States) | 20-Oct-2025 | Corporate Asset Purchase | Buildings and Property | ||
| TJ Biopharma | 08-Feb-2024 | Later Stage VC | Drug Discovery | ||
| Tianzhenshi Biotechnology Company | 23-Mar-2017 | Buyout/LBO | Biotechnology |
NovaBridge Biosciences ESG
Risk Overview
Risk Rating
Updated February, 28, 2023
32.29 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,421
Rank
Percentile
Pharmaceuticals
Industry
of 928
Rank
Percentile
Pharmaceuticals
Subindustry
of 456
Rank
Percentile
NovaBridge Biosciences FAQs
-
When was NovaBridge Biosciences founded?
NovaBridge Biosciences was founded in 2016.
-
Where is NovaBridge Biosciences headquartered?
NovaBridge Biosciences is headquartered in Rockville, MD.
-
What is the size of NovaBridge Biosciences?
NovaBridge Biosciences has 30 total employees.
-
What industry is NovaBridge Biosciences in?
NovaBridge Biosciences’s primary industry is Drug Discovery.
-
Is NovaBridge Biosciences a private or public company?
NovaBridge Biosciences is a Public company.
-
What is NovaBridge Biosciences’s stock symbol?
The ticker symbol for NovaBridge Biosciences is NBP.
-
What is the current stock price of NovaBridge Biosciences?
As of 13-Nov-2026 the stock price of NovaBridge Biosciences is $0.85.
-
What is the current market cap of NovaBridge Biosciences?
The current market capitalization of NovaBridge Biosciences is $98.6M.
-
Who are NovaBridge Biosciences’s competitors?
Agenus, Valerio Therapeutics, Arcus Biosciences, Immunocore Holdings, and Redx Pharma are some of the 77 competitors of NovaBridge Biosciences.
-
What is NovaBridge Biosciences’s annual earnings per share (EPS)?
NovaBridge Biosciences’s EPS for 12 months was -$0.69.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process